Download PDF
Thromb Haemost 2006; 96(05): 660-664
DOI: 10.1160/TH06-06-0337
Endothelium and Vascular Development
Schattauer GmbH

No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease

Svein Solheim
1   Clinical Cardiovascular Research Unit, Department of Cardiology, Ullevål University Hospital, Oslo, Norway
,
Alf Aage Pettersen
1   Clinical Cardiovascular Research Unit, Department of Cardiology, Ullevål University Hospital, Oslo, Norway
,
Harald Arnesen
1   Clinical Cardiovascular Research Unit, Department of Cardiology, Ullevål University Hospital, Oslo, Norway
,
Ingebjørg Seljeflot
1   Clinical Cardiovascular Research Unit, Department of Cardiology, Ullevål University Hospital, Oslo, Norway
› Author Affiliations
Further Information

Publication History

Received 17 June 2006

Accepted after resubmission 24 September 2006

Publication Date:
01 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel. The aim of the present substudy of ASCET was to assess the influence of clopidogrel as compared to aspirin on selected circulating inflammatory markers in patients with stable angiographically verified CHD. Patients on treatment with aspirin 160 mg/day for at least seven days were randomized to either aspirin 160 mg/day (n=105) or clopidogrel 75 mg/day (n=101). Fasting blood samples were drawn at baseline and after one month and after one year for determination of high sensitivity C-reactive protein, tumor necrosis factor α (TNFα), interleukin 6, monocyte chemoattractant protein 1(MCP-1), CD40L, P-selectin, interleukin 10 and transforming growth factor. The groups were similar regarding demographic variables. There were no differences in any variables including changes from baseline to one month and one year between the groups. In the aspirin group we found significantly lower levels of TNFα and MCP-1 after one year; 1.00 versus 1.16 pg/ml (p<0.001) and 245 versus 261 pg/ml (p<0.001), respectively. Likewise, in the clopidogrel group the level of TNFα was significantly reduced after one year; 0.99 versus 1.19 pg/ml (p<0.001). In patients with CHD we found no between-group differences in circulating markers of inflammation after one year treatment with clopidogrel 75 mg/day compared to aspirin 160 mg/day, but in both groups lower levels of TNFα were obtained. The present results indicate similar anti-inflammatory effects of the two drugs.

Keywords

Antiplatelet agents - inflammation - atherosclerosis - randomized trial
 

  • References

  • 1 Carlos T, Kovach N, Schwartz B. et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelialleukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991; 77: 2266-71.
    PubMedGoogle Scholar
  • 2 Graber N, Gopal TV, Wilson D. et al. T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol 1990; 145: 819-30.
    PubMedGoogle Scholar
  • 3 Jang Y, Lincoff AM, Plow EF. et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
    CrossrefPubMedGoogle Scholar
  • 4 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
    CrossrefPubMedGoogle Scholar
  • 5 Berliner JA, Navab M, Fogelman AM. et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
    CrossrefPubMedGoogle Scholar
  • 6 Bevilacqua MP, Pober JS, Mendrick DL. et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238-42.
    CrossrefPubMedGoogle Scholar
  • 7 Frostegard J, Wu R, Haegerstrand A. et al. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 1993; 103: 213-9.
    CrossrefPubMedGoogle Scholar
  • 8 Thornhill MH, Wellicome SM, Mahiouz DL. et al. Tumor necrosis factor combines with IL-4 or IFNgamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592-8.
    PubMedGoogle Scholar
  • 9 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
    CrossrefPubMedGoogle Scholar
  • 10 Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002; 44: 469-78.
    CrossrefPubMedGoogle Scholar
  • 11 Biasucci LM, Liuzzo G, Fantuzzi G. et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-84.
    CrossrefPubMedGoogle Scholar
  • 12 Lindmark E, Diderholm E, Wallentin L. et al. Relationship between interleukin6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001; 286: 2107-13.
    CrossrefPubMedGoogle Scholar
  • 13 Ridker PM, Rifai N, Pfeffer M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
    CrossrefPubMedGoogle Scholar
  • 14 Ridker PM, Rifai N, Stampfer MJ. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
    CrossrefPubMedGoogle Scholar
  • 15 Skoog T, Dichtl W, Boquist S. et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-83.
    CrossrefPubMedGoogle Scholar
  • 16 Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109 (Suppl. 01) II2-10.
    CrossrefPubMedGoogle Scholar
  • 17 Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21: 315-25.
    CrossrefPubMedGoogle Scholar
  • 18 Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161-5.
    CrossrefPubMedGoogle Scholar
  • 19 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
    CrossrefPubMedGoogle Scholar
  • 20 Pinderski LJOslund, Hedrick CC, Olvera T. et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo . Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
    CrossrefPubMedGoogle Scholar
  • 21 Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-87.
    CrossrefPubMedGoogle Scholar
  • 22 Seljeflot I, Hurlen M, Solheim S. et al. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 02: 350-2.
    CrossrefPubMedGoogle Scholar
  • 23 Viles-Gonzalez JF, Anand SX, Valdiviezo C. et al. Update in atherothrombotic disease. Mt Sinai J Med 2004; 71: 197-208.
    PubMedGoogle Scholar
  • 24 Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-4.
    CrossrefPubMedGoogle Scholar
  • 25 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
    CrossrefPubMedGoogle Scholar
  • 26 Kinlay S, Schwartz GG, Olsson AG. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110: 386-91.
    CrossrefPubMedGoogle Scholar
  • 27 Schonbeck U, Varo N, Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
    CrossrefPubMedGoogle Scholar
  • 28 Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005; 06: 21-9.
    PubMedGoogle Scholar
  • 29 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
    CrossrefPubMedGoogle Scholar
  • 30 Solheim S, Arnesen H, Eikvar L. et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92: 843-5.
    CrossrefPubMedGoogle Scholar
  • 31 Ikonomidis I, Andreotti F, Economou E. et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-8.
    CrossrefPubMedGoogle Scholar
  • 32 Pettersen AA, Seljeflot I, Abdelnoor M. et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353-6.
    CrossrefPubMedGoogle Scholar
  • 33 Weber C, Erl W, Pietsch A. et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914-7.
    CrossrefPubMedGoogle Scholar
  • 34 Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-85.
    CrossrefPubMedGoogle Scholar
  • 35 Quinn MJ, Bhatt DL, Zidar F. et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004; 93: 679-84.
    CrossrefPubMedGoogle Scholar
  • 36 Schober A, Manka D, von HP. et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-9.
    CrossrefPubMedGoogle Scholar
  • 37 Muir KW, Weir CJ, Alwan W. et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-5.
    CrossrefPubMedGoogle Scholar
  • 38 Patrono C, Bachmann F, Baigent C. et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur HeartJ 2004; 25: 166-81.
    PubMedGoogle Scholar
  • 39 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
    CrossrefPubMedGoogle Scholar
  • 40 Henn V, Steinbach S, Buchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
    CrossrefPubMedGoogle Scholar
  • 41 Klinkhardt U, Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function?. Semin Thromb Hemost 2005; 31: 400-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Almuti K, Rimawi R, Spevack D. et al. Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
    CrossrefPubMedGoogle Scholar